Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease

Marion C Devers, Stewart Campbell, David Simmons, Marion C Devers, Stewart Campbell, David Simmons

Abstract

Objective: The significance of the metabolic syndrome (MS) is debated. We investigated whether MS component (by ATPIII and IDF definitions) clustering and any association between MS and prevalent cardiovascular disease (CVD) varied with age.

Research design and methods: In all, 1429 adults (≥25 years) from randomly selected households in rural Victoria, Australia, were assessed for components of MS and prevalent CVD. The expected prevalence of MS was calculated following a simple probabilistic model using the prevalence of each MS component.

Results: The observed prevalence of MS was greater than expected: 27.0% vs 21.2% (ATPIII) and 36.0% vs 30.1% (IDF; p<0.0001), based on the prevalence of individual components. There was significant clustering of 4 and 5 MS components in participants <65 years (p<0.0001). CVD was more prevalent in MS participants, 13.5% (IDF), 14.5% (ATPIII) versus 5.3% (no MS) p<0.0001. The OR for CVD in MS participants was greatest in those <45 years OR (95% CI): IDF 17.5 (1.8 to 172); ATPIII 24.3(2.4 to 241), p<0.001 for both, and was not significant in those >65 years. The prevalence of MS (ATPIII) with normal waist circumference (WC) was less than expected (4.8% vs 7.9%, p<0.002). Low levels of high-density lipoprotein and high triglyceride were less common in older MS participants.

Conclusions: ATPIII MS is rare among those with a normal WC. MS components cluster most markedly among those aged <65 years, who also experience substantially greater rates of CVD. Younger patients with MS may warrant more aggressive CVD preventative treatment than suggested by the summation of their individual risk factors.

Keywords: Ageing; Cardiovascular Epidemiology; Mathematical Models and Methods; Metabolic Syndrome.

Figures

Figure 1
Figure 1
Metabolic syndrome—participants with four and five components—expected and observed frequencies by age. No lines: ATP expected, diagonal lines (upward to right): ATP observed, horizontal line: IDF expected, diagonal lines (downward to right): IDF observed. Error bars=95% CI of proportion. p Value is observed versus expected frequencies.
Figure 2
Figure 2
Metabolic syndrome—participants with only three components—expected and observed frequencies by age. No lines: ATP expected, diagonal lines (upward to right): ATP observed, horizontal line: IDF expected, diagonal lines (downward to right): IDF observed. Error bars=95% CI of proportion. p Value is observed versus expected frequencies.

References

    1. Wilson PW, Kannel WB, Silbershatz H et al. . Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999;159:1104–9. 10.1001/archinte.159.10.1104
    1. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769–78.
    1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005;28:2745–9. 10.2337/diacare.28.11.2745
    1. Sumner AD, Sardi GL, Reed JF. Components of the metabolic syndrome differ between young and old adults in the US population. J Clin Hypertens 2012;14:502–6. 10.1111/j.1751-7176.2012.00647.x
    1. Kahn R, Buse J, Ferrannini E et al. . The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684–99.
    1. Sattar N, Welsh P, Preiss D. The insulin resistance syndrome. In: Ferranini E, Zimmet PZ, Alberti G, De Fronzo RA, eds. International textbook of diabetes mellitus. 4th edn Chichester: Wiley Blackwell, 2015:339–412.
    1. Ding EL, Smit LA, Hu FB. The metabolic syndrome as a cluster of risk factors. Is the whole greater than the sum of its parts? Arch Intern Med 2010;170:484–5.
    1. Mozaffarian D, Kamineni A, Prineas RJ et al. . Metabolic syndrome and mortality in older adults. The cardiovascular health study. Arch Intern Med 2008;168:969–78.
    1. Guembe MJ, Toledo E, Barba J et al. . Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA- study. Atherosclerosis 2010;211:612–17. 10.1016/j.atherosclerosis.2010.03.004
    1. Haring R, Wallaschofski H, Nauck M et al. . Total and cardiovascular disease mortality predicted by metabolic syndrome is inferior relative to its components. Exp Clin Endocrinol Diabetes 2010;118:685–91.
    1. Morley JE, Sinclair A. The metabolic syndrome in older persons: a loosely defined constellation of symptoms or a distinct entity? Age Ageing 2009;38:494–7.
    1. Girman CJ, Rhodes T, Mercuri M et al. . The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136–41. 10.1016/j.amjcard.2003.09.028
    1. Sundström J, Risérus U, Byberg L et al. . Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878–82. 10.1136/bmj.38766.624097.1F
    1. Pajunen P, Rissanen H, Härkänen T et al. . The metabolic syndrome as a predictor of incident diabetes and cardiovascular events in the Health 2000 Study. Diab Metab 2010;36:395–401.
    1. Sattar N, Gaw A, Scherbakova O et al. . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003;108:414–19. 10.1161/01.CIR.0000080897.52664.94
    1. Lakka H-M, Laaksonen DE, Lakka TA et al. . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–16.
    1. Scuteri A, Morrell CH, Najjar SS et al. . The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005;28:882–7. 10.2337/diacare.28.4.882
    1. Rachas A, Raffaitin C, Barberger-Gateau P et al. . Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart 2012;98:650–5.
    1. Sattar N, McConnachie A, Shaper AG et al. . Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927–35. 10.1016/S0140-6736(08)60602-9
    1. Salminen M, Kuoppamäki M, Vahlberg T et al. . The metabolic syndrome defined by modified International Diabetes Federation criteria and mortality: a 9-year follow-up of the aged in Finland. Diabetes Metab 2010;36:437–44.
    1. Samaras K, Crawford J, Baune BT et al. . The value of the metabolic syndrome concept in elderly adults: is it worth less than the sum of its parts? J Am Geriatr Soc 2012;60:1734–41. 10.1111/j.1532-5415.2012.04105.x
    1. Thomas F, Pannier B, Benetos A et al. . The impact of the metabolic syndrome- but not of hypertension- on all-cause mortality disappears in the elderly. J Hypertens 2011;29:663–8. 10.1097/HJH.0b013e32834320dc
    1. Monami M, Lamanna C, Balzi D et al. . Metabolic syndrome and cardiovascular mortality in older type 2 diabetic patients: a longitudinal study. J Gerontol A Biol Sci Med Sci 2008;63:646–9. 10.1093/gerona/63.6.646
    1. Forti P, Pirazzoli GL, Maltoni B et al. . Metabolic syndrome and all-cause mortality in older men and women. Eur J Clin Invest 2012;42:1000–9. 10.1111/j.1365-2362.2012.02688.x
    1. Lin J-W, Caffrey JL, Chang M-H et al. . Sex, menopause, metabolic syndrome, and all- cause and cause- specific mortality- cohort analysis from the third national health and nutrition examination survey. J Clin Endocrinol Metab 2010;95:4258–67. 10.1210/jc.2010-0332
    1. Vishram JK, Borglykke A, Andreasen AH et al. . Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM prospective cohort project. PLoS ONE 2014;9:e107294.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
    1. Alberti KG, Zimmet PZ, Shaw J. Metabolic syndrome- a new world- wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469–80.
    1. Simmons D, McKenzie A, Eaton A et al. . Prevalence of diabetes in rural Victoria. Diabetes Res Clin Pract 2005;70:287–90. 10.1016/j.diabres.2005.04.004
    1. Simmons D, Shaw J, McKenzie A et al. . Is grand multiparity associated with an increased risk of dysglycaemia? Diabetologia 2006;49:1522–7. 10.1007/s00125-006-0276-6
    1. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873–90. 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>;2-I
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53.
    1. Alberti KG, Eckel RH, Grundy SM et al. . Harmonizing the metabolic syndrome: a joint interim statement of the IDF Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; AHA; World Heart Federation and International Association for the Study of Obesity. Circulation 2009;120:1640–5. 10.1161/CIRCULATIONAHA.109.192644
    1. Mottillo S, Filion KB, Genest J et al. . The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–32. 10.1016/j.jacc.2010.05.034
    1. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:2444–9. 10.2337/diacare.27.10.2444
    1. Cameron AJ, Magliano DJ, Zimmet PZ et al. . The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007;77:471–8. 10.1016/j.diabres.2007.02.002
    1. Pladevall M, Singal B, Williams LK et al. . A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 2006;29:113–22. 10.2337/diacare.29.01.06.dc05-0862
    1. Goodman E, Dolan LM, Morrison JA et al. . Factor analysis of clustered cardiovascular risks in adolescence. Obesity is the predominant correlate of risk among youth. Circulation 2005;111:1970–7.
    1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73–8. 10.1136/bmj.38678.389583.7C
    1. Beltrán-Sánchez H, Harhay MO, Harhay MM et al. . Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol 2013;62:697–703.
    1. Katzmarzyk PT, Janssen I, Ross R et al. . The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care 2006;29:404–40. 10.2337/diacare.29.02.06.dc05-1636

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する